IMPACT THERAP-B (07630): Senaparib Receives European Commission Approval for Marketing
IMPACT THERAP-B (07630) announced that the Company's independently developed innovative drug Senaparib (Chinese trade name: Paisuning, overseas trade name: Sepalna) has officially received the final decision from the European Commission (EC) approving its use for maintenance treatment of advanced epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. This approval was made by the European Commission (EC) based on the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Senaparib has thus become the first China-developed PARP inhibitor approved in the EU for first-line maintenance treatment of the full population of advanced ovarian cancer, marking another breakthrough for a domestically developed innovative targeted ovarian cancer drug in the European market.
IMPACT THERAP-B (07630) announced that the Company's independently developed innovative drug senaparib (Chinese trade name: , overseas trade name: Sepalna) has officially received a final decision from the European Commission (EC) approving it for the maintenance treatment of advanced epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. This approval was made by the European Commission (EC) based on the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Senaparib has thus become the first China-originated PARP inhibitor approved in the EU for first-line maintenance treatment of the full population of advanced ovarian cancer, marking another breakthrough for a domestically developed targeted innovative drug for ovarian cancer in the European market.
Senaparib (Sepalna) is a novel, highly active PARP1/2 inhibitor independently developed by the Company. Its unique molecular structure ensures excellent target selectivity and a broad safety window. Senaparib capsules were approved by China's National Medical Products Administration in January 2025 for use as first-line maintenance treatment in adult patients with advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have achieved a complete or partial response to platinum-based chemotherapy, and were subsequently included in the National Reimbursement Drug List in December 2025. The Company is actively advancing the global clinical and regulatory development of senaparib. At the same time, the Company is also advancing the lifecycle management of senaparib, exploring combination therapy opportunities, and expanding into multiple indications.
Related Articles

HK Bull/Bear Outstanding Qty Ratio(52:48) | November 17

Agora, Inc. Sponsored ADR Class A (API.US) Q3 revenue up 19% year-over-year, profitable for the eighth consecutive quarter.

STAR CM (06698) repurchased 15,800 shares for HK$12,500 on November 16.
HK Bull/Bear Outstanding Qty Ratio(52:48) | November 17

Agora, Inc. Sponsored ADR Class A (API.US) Q3 revenue up 19% year-over-year, profitable for the eighth consecutive quarter.

STAR CM (06698) repurchased 15,800 shares for HK$12,500 on November 16.






